Journal Club VL

Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 Journal Club – Christopher Wallis & Zachary...

Details
In this UroToday GU Oncology Journal Club, Christopher Wallis and Zachary Klaassen highlight a Journal of Clinical Oncology publication on a phase two open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma, progressing after platinum-based chemotherapy and checkpoint inhibitors. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With M...

Durvalumab Combination in Advanced Urothelial Cancer based on an Adaptive Biomarker-driven Trial Design - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club Christopher Wallis and Zachary Klaassenthey discuss, “An Adaptive Biomarker-Directed Platform Study of Durvalumab in Combination with Targeted Therapies in Advanced Urothelial Cancer”. This Journal Club kicks off with an overview of advanced urothelial carcinoma, which then transitions into a discussion on the background and controls of this study. About halfway throu...

Abiraterone Acetate Plus Prednisone in Black and White Men with Metastatic Castrate-Resistant Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a retrospective analysis of randomized trials that suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men, a prospective study of abiraterone acetate plus prednisone to explore outcomes by race. The goal of this study was to first demonstrate the feasibili...

A Phase 1 Trial and Biomarker Analysis of HIF-2α in Renal Cell Carcinoma With Belzutifan (MK-6482), Journal Club – Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the first-in-human phase 1 study of belzutifan (MK-6482), a potent, selective small molecule inhibitor of Hypoxia-inducible factor-2α (HIF-2α). HIF-2α is a transcription factor that frequently accumulates in clear cell renal cell carcinoma (ccRCC), resulting in the constitutive activation of genes involved in carcinogen...

Treatment Effect of 177Lu-PSMA in Low-Volume mHSPC Patients, Journal Club – Christopher Wallis & Zachary Klaassen

Details
In this UroToday journal club, Christopher Wallis and Zachary Klaassen discuss a pilot study on Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients. The discussion begins with a look into the evolution of mHSPC treatment over the past five years, with an acknowledgment of the CHAARTED, STAMPEDE, and GETUG trials. Dr. Wallis also discusses the prevalenc...

18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the Clinical Cancer Research publication on the results from the CONDOR Phase 3, multicenter study. In particular, conventional imaging performs poorly when PSA levels are low, less than 2 ng/mL, and the use of novel PET radiotracers may address this issue and provide more sensitive imaging. CONDOR was a prospective stu...

Improved Survival for Men Treated With Enzalutamide Added to Testosterone Suppression Who Present With Distant Metastases Years After Diagnosis of mHSPC Journal Club – Christopher Wallis and Zachary K...

Details
In this Journal Club, Christopher Wallis and Zachary Klaassen highlight a subset analysis from the ENZAMET trial looking at the impact of enzalutamide on survival outcomes in men whose cancer comes back years later after diagnosis. The ENZAMET trial randomly assigned 1,125 metastatic hormone-sensitive prostate cancer (mHSPC) patients from March 31, 2014, to March 24, 2017: 562 in the non-steroidal...

The BRAVO-Feasibility Study, Intravesical Maintenance BCG vs Radical Cystectomy in BCG-Naive Patients, A UroToday Journal Club - Christopher Wallis & Zachary Klaassen

Details
The BRAVO-Feasibility Study was designed to understand whether a randomized trial comparing intravesical maintenance Bacillus Calmette-Guerin (BCG) and radical cystectomy (RC) for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC) is possible. This trial was a two-arm, prospective multicenter randomized study to determine the feasibility in BCG-naive patients, in which patients...

A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher...

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight a systematic review and meta-analysis examining the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer, an article published in European Urology. Drs. Wallis and Klaassen detail the analysis, objective,...

The Diagnostic Performance of PSMA PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss The Journal of Urology publication on the Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). Prostate cancer staging is critical in multiple steps in the disease continuum, from the initial diagnosis to the...